7月29日，布鲁克盘中上涨5.18%，报63.16美元/股，成交额9610.28万美元。
消息面上，公司近期完成对Noscendo旗下Disqver临床宏基因组测序平台的收购，进一步拓展基于新一代测序技术的感染检测产品组合，该平台可直接从血液样本中快速检测病原体，有望提升败血症等危急感染的诊断效率。此外，美银证券近期将公司目标价从65美元上调至70美元，维持增持评级。同日生命科学工具板块整体走强，Repligen涨13.85%，艾昆纬涨13.58%，赛默飞世尔涨2.24%，丹纳赫涨1.79%。公司下次财报将于8月4日盘前发布。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.